Lead Product(s) : SP-002,Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Stamford Pharmaceuticals Announces First Patient Treated with SP-002 in Phase 2 BCC Study
Details : SP-002 is an adenovirus-based biologic producing Interferon-g, under investigation with vismodegib for locally advanced metastatic basal cell carcinoma.
Product Name : SP-002
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 04, 2024
Lead Product(s) : SP-002,Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
